|
Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Takeda |
|
|
Honoraria - Celgene; Onyx |
Consulting or Advisory Role - Celgene; Onyx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Janssen |
Speakers' Bureau - Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Janssen |
|
David Samuel DiCapua Siegel |
Honoraria - Celgene; Millennium; Onyx |
Speakers' Bureau - Celgene; Millennium; Onyx |
|
|
No Relationships to Disclose |
|
Vesselina Goranova-Marinova |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Millennium; Onyx |
Speakers' Bureau - Celgene; Millennium; Onyx |
Research Funding - Celgene; Millennium; Onyx |
Travel, Accommodations, Expenses - Celgene; Millennium; Onyx |
|
|
|
Consulting or Advisory Role - Onyx |
|
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; MSD; Novartis; Onyx |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Novartis; Onyx; Sanofi |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Onyx |